Merus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.

About MRUS

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. 

CEO
Sven Ante Lundberg
CEOSven Ante Lundberg
Employees
260
Employees260
Headquarters
Utrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded
2003
Founded2003
Employees
260
Employees260

MRUS Key Statistics

Market cap
7.16B
Market cap7.16B
Price-Earnings ratio
-17.06
Price-Earnings ratio-17.06
Dividend yield
Dividend yield
Average volume
2.81M
Average volume2.81M
High today
High today
Low today
Low today
Open price
$94.80
Open price$94.80
Volume
0.00
Volume0.00
52 Week high
$95.04
52 Week high$95.04
52 Week low
$33.19
52 Week low$33.19

MRUS News

Simply Wall St 12h
Merus: Reviewing Valuation Following Strong Share Price Gains

Merus (MRUS) stock has delivered an impressive run, up 39% over the past month and 124% year-to-date. Investors are taking note because these gains come amid co...

Merus: Reviewing Valuation Following Strong Share Price Gains
TipRanks 6d
Cautious Optimism for Merus’s Petosemtamab in mCRC Amidst Limited Data, Hold Rating Maintained

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Merus and keeping the price target at $97.00. Elevate Your Investing Strategy: Take advantag...

TipRanks 7d
Oppenheimer positive on CytomX after Merus colon cancer data

Oppenheimer says Merus’ (MRUS) colon cancer data update reinforces its “enthusiasm” for CytomX Therapeutics’ (CTMX) dose expansion data. The Merus Phase 2 resul...

Analyst ratings

88%

of 17 ratings
Buy
11.8%
Hold
88.2%
Sell
0%

More MRUS News

TipRanks 7d
Hold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy

Needham analyst Ami Fadia has maintained their neutral stance on MRUS stock, giving a Hold rating yesterday. Elevate Your Investing Strategy: Take advantage of...

TipRanks 7d
Merus announces initial interim data from phase 2 trial of petosemtamab

Merus (MRUS) N.V. announced initial interim clinical data as of an April 28, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemt...

People also own

Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.